[go: up one dir, main page]

IN2014MN01754A - - Google Patents

Info

Publication number
IN2014MN01754A
IN2014MN01754A IN1754MUN2014A IN2014MN01754A IN 2014MN01754 A IN2014MN01754 A IN 2014MN01754A IN 1754MUN2014 A IN1754MUN2014 A IN 1754MUN2014A IN 2014MN01754 A IN2014MN01754 A IN 2014MN01754A
Authority
IN
India
Prior art keywords
formula
present
compounds
heteroaryl
comounds
Prior art date
Application number
Other languages
English (en)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01754(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Priority to IN1754MUN2014 priority Critical patent/IN2014MN01754A/en
Publication of IN2014MN01754A publication Critical patent/IN2014MN01754A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
IN1754MUN2014 2012-03-14 2013-03-11 IN2014MN01754A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1754MUN2014 IN2014MN01754A (ja) 2012-03-14 2013-03-11

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051915 WO2013136254A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds
IN1754MUN2014 IN2014MN01754A (ja) 2012-03-14 2013-03-11

Publications (1)

Publication Number Publication Date
IN2014MN01754A true IN2014MN01754A (ja) 2015-07-03

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1754MUN2014 IN2014MN01754A (ja) 2012-03-14 2013-03-11
IN1755MUN2014 IN2014MN01755A (ja) 2012-03-14 2013-03-11

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN1755MUN2014 IN2014MN01755A (ja) 2012-03-14 2013-03-11

Country Status (36)

Country Link
US (5) US9428499B2 (ja)
EP (2) EP2834236B1 (ja)
JP (3) JP6093384B2 (ja)
KR (4) KR20140138911A (ja)
CN (4) CN104203947A (ja)
AP (2) AP3859A (ja)
AU (4) AU2013234014B2 (ja)
BR (1) BR112014022713B1 (ja)
CA (2) CA2865164C (ja)
CL (2) CL2014002411A1 (ja)
CO (2) CO7160029A2 (ja)
CR (2) CR20140463A (ja)
CU (2) CU24335B1 (ja)
DK (2) DK2834236T3 (ja)
DO (2) DOP2014000203A (ja)
EA (2) EA028232B1 (ja)
ES (2) ES2741896T3 (ja)
GE (2) GEP201706774B (ja)
GT (2) GT201400196A (ja)
HK (2) HK1202538A1 (ja)
IL (2) IL234559A (ja)
IN (2) IN2014MN01754A (ja)
MA (2) MA37400B1 (ja)
MX (3) MX355474B (ja)
MY (2) MY175950A (ja)
NI (2) NI201400108A (ja)
NZ (2) NZ629432A (ja)
PE (2) PE20141974A1 (ja)
PH (2) PH12014502040B1 (ja)
PL (1) PL2834237T3 (ja)
SG (2) SG11201405007QA (ja)
TN (2) TN2014000357A1 (ja)
TR (1) TR201811976T4 (ja)
UA (2) UA114907C2 (ja)
WO (2) WO2013136254A1 (ja)
ZA (1) ZA201406186B (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PE20141974A1 (es) 2012-03-14 2014-12-12 Lupin Ltd Compuestos de heterociclilo
DK3176170T3 (en) 2012-06-13 2019-01-28 Incyte Holdings Corp SUBSTITUTED TRICYCLIC RELATIONS AS FGFR INHIBITORS
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA3130452C (en) 2013-04-19 2023-10-31 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
PT3061747T (pt) * 2013-10-25 2021-05-04 Shanghai hengrui pharmaceutical co ltd Derivados pirídicos de cetona, método para preparar os mesmos e aplicação farmacêutica dos mesmos
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS64167B1 (sr) * 2017-12-21 2023-05-31 Boehringer Ingelheim Int Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
BR112021024532A2 (pt) 2019-06-19 2022-05-24 Boehringer Ingelheim Int Terapia combinada anticâncer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3146052A1 (en) * 2019-07-30 2021-02-04 Edvince Ab Mek inhibitor for treatment of stroke
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021285032A1 (en) * 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
EP4319757A1 (en) 2021-04-09 2024-02-14 Boehringer Ingelheim International GmbH Anticancer therapy
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
CA3215081A1 (en) * 2021-04-16 2022-10-20 Alfredo C. Castro Mek inhibitors and uses thereof
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN118613485A (zh) 2021-12-01 2024-09-06 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
AU2022402390A1 (en) 2021-12-01 2024-05-30 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441051A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
SI1470124T1 (sl) * 2002-01-22 2006-04-30 Warner Lambert Co 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL1689233T3 (pl) 2003-11-19 2012-11-30 Array Biopharma Inc Bicykliczne inhibitory MEK
SI2298768T1 (en) * 2004-06-11 2013-01-31 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyridoS2,3-dCpyrimidine derivatives and related compounds for the treatment of cancer
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MX2011011083A (es) 2009-04-21 2011-11-04 Novartis Ag Compuestos heterociclicos como inhibidores de mek.
PE20141974A1 (es) * 2012-03-14 2014-12-12 Lupin Ltd Compuestos de heterociclilo

Also Published As

Publication number Publication date
JP2018115215A (ja) 2018-07-26
PH12014502040A1 (en) 2014-11-24
TR201811976T4 (tr) 2018-09-21
MX355474B (es) 2018-04-16
SG11201405007QA (en) 2014-10-30
IL234560A (en) 2017-06-29
PH12014502040B1 (en) 2014-11-24
CN107698585A (zh) 2018-02-16
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
EP2834237A1 (en) 2015-02-11
IN2014MN01755A (ja) 2015-07-03
CA2865164A1 (en) 2013-09-19
CA2865167A1 (en) 2013-09-19
AU2013234009A1 (en) 2014-09-25
CU24335B1 (es) 2018-04-03
AP2014008008A0 (en) 2014-10-31
UA114907C2 (uk) 2017-08-28
AU2013234009B2 (en) 2016-10-27
CU20140109A7 (es) 2014-11-27
UA114906C2 (uk) 2017-08-28
GEP201706671B (en) 2017-05-25
CU24272B1 (es) 2017-08-08
TN2014000357A1 (en) 2015-12-21
CN108383836B (zh) 2021-11-12
EP2834236A1 (en) 2015-02-11
AU2013234014B2 (en) 2017-02-02
MX2014010928A (es) 2015-04-10
DOP2014000204A (es) 2015-02-15
PH12014502041A1 (en) 2014-11-24
US20150133424A1 (en) 2015-05-14
CN104271577A (zh) 2015-01-07
MA37405A1 (fr) 2016-03-31
MY174188A (en) 2020-03-12
GT201400195A (es) 2017-11-09
CR20140464A (es) 2014-11-28
MX355526B (es) 2018-04-20
EA029768B1 (ru) 2018-05-31
NI201400107A (es) 2014-11-26
US20170112840A1 (en) 2017-04-27
PE20141974A1 (es) 2014-12-12
GEP201706774B (en) 2017-11-27
HK1202538A1 (en) 2015-10-02
CL2014002411A1 (es) 2015-04-06
US20160331753A1 (en) 2016-11-17
CR20140463A (es) 2014-11-28
WO2013136254A1 (en) 2013-09-19
SG11201405006PA (en) 2014-10-30
KR20140138910A (ko) 2014-12-04
PH12014502041B1 (en) 2014-11-24
JP6630771B2 (ja) 2020-01-15
EA028232B1 (ru) 2017-10-31
PE20141973A1 (es) 2014-12-12
CA2865164C (en) 2021-06-08
ES2684517T3 (es) 2018-10-03
KR20190073597A (ko) 2019-06-26
CN104203947A (zh) 2014-12-10
IL234559A (en) 2017-06-29
DOP2014000203A (es) 2015-02-15
KR20140138911A (ko) 2014-12-04
AU2018202568B2 (en) 2019-05-09
JP2015514056A (ja) 2015-05-18
CA2865167C (en) 2019-08-06
DK2834237T3 (en) 2018-08-27
EA201491671A1 (ru) 2014-12-30
BR112014022713A2 (ja) 2017-06-20
CO7160029A2 (es) 2015-01-15
CN108383836A (zh) 2018-08-10
CL2014002412A1 (es) 2015-03-06
KR20190100472A (ko) 2019-08-28
JP2015509975A (ja) 2015-04-02
ES2741896T3 (es) 2020-02-12
US20150299186A1 (en) 2015-10-22
AU2018202568A1 (en) 2018-05-10
PL2834237T3 (pl) 2018-11-30
US9827247B2 (en) 2017-11-28
US9573944B2 (en) 2017-02-21
KR102241111B1 (ko) 2021-04-15
GT201400196A (es) 2017-09-28
MA37400B1 (fr) 2019-11-29
ZA201406186B (en) 2016-06-29
CU20140110A7 (es) 2014-11-27
CO7170131A2 (es) 2015-01-28
AU2017200493A1 (en) 2017-02-16
JP6093384B2 (ja) 2017-03-08
US20170101408A1 (en) 2017-04-13
EA201491672A1 (ru) 2014-12-30
US9428499B2 (en) 2016-08-30
JP6431770B2 (ja) 2018-11-28
NZ629432A (en) 2017-01-27
US9969731B2 (en) 2018-05-15
KR102240101B1 (ko) 2021-04-14
DK2834236T3 (da) 2019-08-26
EP2834236B1 (en) 2019-05-22
US9555035B2 (en) 2017-01-31
HK1206020A1 (en) 2015-12-31
AP2014008009A0 (en) 2014-10-31
AU2017200493B2 (en) 2018-03-29
NZ629442A (en) 2016-12-23
MX366426B (es) 2019-07-08
AP3859A (en) 2016-10-31
EP2834237B1 (en) 2018-06-06
MA37400A1 (fr) 2016-05-31
MX2014010925A (es) 2015-04-10
AU2013234014A1 (en) 2014-09-25
BR112014022713B1 (pt) 2021-09-08
AP3834A (en) 2016-09-30
WO2013136249A1 (en) 2013-09-19
NI201400108A (es) 2014-11-28

Similar Documents

Publication Publication Date Title
IN2014MN01754A (ja)
UA109010C2 (en) Morpholino pyrividines and their use in therapy
UA117122C2 (uk) Хінолонові похідні
PH12014502605A1 (en) Uracyl spirooxetane nucleosides
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014MN02598A (ja)
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
IN2014CN00568A (ja)
PH12014502524A1 (en) Carboxylic acid compounds
IN2015DN01119A (ja)
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
IN2015DN02109A (ja)
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors